A detailed history of Lmr Partners LLP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Lmr Partners LLP holds 395,857 shares of BPMC stock, worth $51.2 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares
395,857
Previous 10,689 3603.41%
Holding current value
$51.2 Million
Previous $946,000 5263.64%
% of portfolio
0.48%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$79.22 - $128.4 $30.5 Million - $49.5 Million
385,168 Added 3603.41%
395,857 $50.7 Million
Q1 2025

May 15, 2025

BUY
$86.69 - $115.63 $926,629 - $1.24 Million
10,689 New
10,689 $946,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $7.73B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.